Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Vytorin by Year
Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%) (%)
Merck Vytorin: -36.0% in FY2020, up 7.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2020
-36.0%
Period ended Dec 31, 2020
Change on a year earlier
+7.0 pts
-43.0% in FY2019
History
4 years
Since FY2017
Sources
4
Documents cited below
Where the FY2020 figure comes from
“|| Vytorin | 53 | 39 | 47 | 43 | 182 | 97 | 76 | 57 | 54 | 285 | -19 | -20 | -36 | -34”
Source: Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | -36.0% | +7.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -43.0% | -9.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -34.0% | 0.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | -34.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Vytorin (%), annual FY2017–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vytorin-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.